Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2024-05-22

Original market date: See footnote 1

2024-05-22

Product name:

ABRYSVO

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02544040

Product Monograph/Veterinary Labelling:

Date: 2023-12-21 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

PFIZER CANADA ULC
17300 Trans-Canada Highway
Kirkland
Quebec
Canada H9J 2M5

Class:

Human

Dosage form(s):

Powder For Solution ,  Kit

Route(s) of administration:

Intramuscular

Number of active ingredient(s):

2

Schedule(s):

Schedule D

 

American Hospital Formulary Service (AHFS): See footnote 3

80:12.00 

Anatomical Therapeutic Chemical (ATC): See footnote 4

J07BX05 RESPIRATORY SYNCYTIAL VIRUS VACCINE

Active ingredient group (AIG) number:See footnote5

0265562001

List of active ingredient(s)
Active ingredient(s) See footnote8 Strength
RSV SUBGROUP A STABILIZED PREFUSION F PROTEIN 60 MCG / 0.5 ML
RSV SUBGROUP B STABILIZED PREFUSION F PROTEIN 60 MCG / 0.5 ML

Risk Management Plans See footnote 7

A Risk Management Plan (RMP) for this product was submitted.

Pharmacovigilance/Monitoring Activity
Clinical Trials
Observational Studies
Registry
Version 4.0.3

"Page details"

Date modified: